

Remarks

In the Office Action of May 17, 2006, the Examiner rejected the pending claims for nonstatutory obviousness-type double patenting over U.S. Patent No. 6,602,520 (the parent patent to this divisional application). Applicant encloses a terminal disclaimer to overcome this rejection. Also enclosed is a copy of the assignment in the parent application, recorded at Reel 012661, Frame 0009.

Applicant directs the Examiner's attention to Serial No. 10/030,456, the parent application of this application. In the Interview Summary Record, Paper Number 9, the comments from Examiner Rose may appear to suggest that applicant conceded that the prior art disclosed identical processes that make (a) porous effervescent tablets that quickly dissolve with no disintegrant and (b) tablets with disintegrants that are not effervescent. Applicant, however, only agreed that the claims to be allowed in that case were not taught or suggested by the cited art. Applicant did not reach agreement with any aspects of the cited art not pertinent to the allowed claims.

Respectfully Submitted,



Richard S. Bullitt
Reg. No. 30,733
(973) 408-8229

Bayer HealthCare LLC
36 Columbia Road
Morristown, NJ 07962